• Work with us
  • External Contractors
Fondazione Toscana Life Sciences
  • IT
  • EN
Toscana Life Sciences
  • THE FOUNDATION
    • Organization
    • History
    • Membership
    • The Legislative Decree No. 231/2001
  • Activity
  • Cluster
  • ITS VITA
  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies
  • Services
    • Business development services
    • Research services
    • Incubation services
    • Protection of intellectual property
  • Projects
    • Monoclonal Antibody Discovery (MAD) LAB
    • ERC Advanced Grant VACCIBIOME
    • TUMOUR IMMUNOLOGY UNIT
    • BOTANICALS LAB
    • Data Science for Health (DaScH) Lab
    • Regions4PerMed
    • IDF SHARID
    • BORNTOGEtTHERe
    • SINO-EU‐PERMED
    • Orphan diseases
  • Disseminating
    • TLS Open Doors
    • Scientists for a day
    • Science + Economy = Business
    • Researcher’s Night
    • European Biotech Week
  • TLS4Covid19
  • Stories
Enter any keyword and press enter

Exosomics

  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies

Exosomics

Established in 2012 and hosted in one of the largest and more active bio-parks in Italy, Tuscany Life Sciences. The company is active in the area of Liquid Biopsy in cancer and after several years of R&D work and IP development, is now at commercial stage launching its proprietary and innovative solutions into the molecular diagnostics market.

Exosomics’ distinguishing factor is the capability to isolate tumor-derived exosomes through proprietary affinity methods, thus enriching for tumor-derived proteins, DNA and RNA, and therefore significantly improving molecular diagnostics in cancer and allowing early pan-cancer screening.

Given that tumor-derived exosomes contain biomarkers identical to those expressed on a cancer cell surface, and poorly expressed in healthy individuals, Exosomics considers exosome-based liquid biopsy as the next generation of cancer diagnostics, which will not only complement but surpass traditional biopsy.
The company’s mid/long term goal is to develop a pan-cancer test that will fulfill a critical unmet medical need by enabling early screening of multiple cancer types.

Exosomics’ superior know-how and expertise in Liquid Biopsy has attracted several research groups, both Academic and from Biotech/Pharma, who are using its platform and services to address several relevant questions in diagnostics and new therapeutic development.
To ensure the highest available quality standards, Exosomics is both ISO 9001 and ISO 13485 certified and GCLP accredited.

www.exosomics.eu

Fondazione Toscana Life Sciences
Via Fiorentina, 1
53100 Siena – ITALIA

  • tel +39 0577 231211
  • fax +39 0577 43444
  • info@toscanalifesciences.org; info@pec.fondazionetls.org

Twitter Feeds

🗣Nuovo appuntamento con Region4PerMed. 📍Lunedì 27 e martedì 28 giugno Siena ospita la nuova conferenza del progetto…

@FondazioneTLS 3 Hours Ago

🗣Nuovo appuntamento con @Regions4PerMed 📍Lunedì 27 giugno e martedì 28 giugno, Siena ospita la nuova conferenza su…

@FondazioneTLS 23 Hours Ago

La Fondazione Tls è alla ricerca di un Senior Data Scientist (Computational Structural Biologist). 🗣 Per candidart…

@FondazioneTLS About a Day Ago

Contatti

    Concedo il consenso al trattamento dei dati personali secondo la nostra Privacy Policy per poter essere contattato da Fondazione Toscana Life Sciences.

©2015-2021 - Fondazione Toscana Life Sciences - P.I. 01194710529 - Codice SDI: SUBM70N - Privacy - Cookie Policy